Matthew R. Henn files SEC Form 4 disclosures for Seres Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2025, most recently 2026-08-17.
CIK 0001767321
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MCRB | 7,995 | $17K |
Shares reported on the most recent Form 4, priced at the 2026-08-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MCRB | SELL · 10b5-1 | 2026-08-17 | 2026-08-18 | $4.55 | $369 | +13.1% | -8.2% | — |
| MCRB | SELL · 10b5-1 | 2026-05-18 | 2026-05-19 | $7.53 | $580 | -4.3% | -13.0% | -40.6% |
| MCRB | SELL | 2026-02-15 | 2026-02-18 | $8.47 | $754 | +8.9% | +2.7% | -9.1% |
| MCRB | SELL · 10b5-1 | 2025-11-15 | 2025-11-18 | $17.30 | $22K | -27.1% | -35.8% | -65.2% |
| MCRB | SELL · 10b5-1 | 2025-08-18 | 2025-08-19 | $16.65 | $1K | +16.3% | +10.7% | +32.9% |
| MCRB | SELL · 10b5-1 | 2025-05-16 | 2025-05-19 | $7.28 | $561 | -11.2% | -2.6% | +122.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.